Clinical Trial Update: Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating avelumab and cetuximab with gemcitabine and cisplatin in squamous non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Avelumab (avelumab)
• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-11-09